Verve Therapeutics Inc VERV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VERV is a good fit for your portfolio.
News
-
Attention Verve Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
-
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
-
Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback
-
Verve Therapeutics Announces Updates on its PCSK9 Program
-
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Trading Information
- Previous Close Price
- $6.74
- Day Range
- $6.53–6.86
- 52-Week Range
- $6.53–21.42
- Bid/Ask
- $6.51 / $6.80
- Market Cap
- $556.90 Mil
- Volume/Avg
- 479 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 36.35
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 255
- Website
- https://www.vervetx.com
Comparables
Valuation
|
Metric
|
VERV
|
CELC
|
RCKT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.91 | 2.99 | 4.30 |
Price/Sales | 36.35 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VERV
|
CELC
|
RCKT
|
|---|---|---|---|
Quick Ratio | 17.02 | 12.78 | 7.69 |
Current Ratio | 17.24 | 13.43 | 7.80 |
Interest Coverage | — | −12.43 | −138.48 |
Quick Ratio
VERV
CELC
RCKT
Profitability
|
Metric
|
VERV
|
CELC
|
RCKT
|
|---|---|---|---|
Return on Assets (Normalized) | −26.37% | −35.57% | −38.11% |
Return on Equity (Normalized) | −33.33% | −49.08% | −43.04% |
Return on Invested Capital (Normalized) | −32.02% | −39.21% | −43.72% |
Return on Assets
VERV
CELC
RCKT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dkspndztlz | Pcf | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jwkfrnrwg | Mcwykp | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qdbkhxgt | Rjhzn | $98.1 Bil | |
MRNA
| Moderna Inc | Pymtqjr | Ptk | $39.1 Bil | |
ARGX
| argenx SE ADR | Dvwqyxk | Svygg | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Bdmdqhdb | Kvmcw | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Brppjwk | Slpscy | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xlhdckrw | Rmwyk | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tjvqycszmv | Vslywn | $12.5 Bil | |
INCY
| Incyte Corp | Nmdqqwwcs | Cmncjj | $11.9 Bil |